At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
saracatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of AZD0530 in Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating saracatinib for Recurrent Melanoma and 4 related conditions. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This phase II trial is studying how well saracatinib works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IV Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedApr 2008
Primary CompletionJan 2011
TodayJul 2026
First PostedApr 29, 2008
Enrollment StartJul 1, 2006
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 18.2 years ago
Interventions
saracatinibdrug